TORONTO, ONTARIO and SAINT LAURENT, QUEBEC -- (MARKET WIRE) -- March 20, 2007 -- Cannasat Therapeutics Inc. (TSX VENTURE: CTH) and IntelGenx Corp. (OTCBB: IGXT) today announced a long-term collaborative agreement to co-develop a novel cannabinoid-based product, CAT 320, through a combination of Cannasat's and IntelGenx's proprietary drug delivery technologies.
